BC Partners Starts $1.8bn Pharmathen Sale with Jefferies Hire

BC Partners has begun the sale of Greek drugmaker Pharmathen, one of two healthcare divestments worth more than $3.6bn that the buyout firm wants to complete this year, with the hiring of investment bank Jefferies, two sources said.

Pharmathen focuses on developing, manufacturing and out-licensing complex generic drugs and could be valued at about $1.8bn, the sources told Reuters, speaking on condition of anonymity.

BC Partners is a British international investment firm with over $40bn of assets under management across private equity, credit and real estate in Europe and North America.

BC Partners declined to comment. Jefferies was not immediately available for comment.

Source: Reuters